Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Bexxar

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
UNLABELLED The study aimed at identifying patient-specific dosimetric and nondosimetric factors predicting outcome of non-Hodgkin… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
2009
2009
IntroductionThe American Cancer Society estimated 66,120 new cases of non-Hodgkin lymphoma (NHL) in the USA in 2008… Expand
  • table 2
  • table 1
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2007
2007
  • Ken Garber
  • Journal of the National Cancer Institute
  • 2007
  • Corpus ID: 41607315
Y-labeled ibritumomab) at a San Francisco investors’ conference. The U.S. Food and Drug Admi nistration had recently approved… Expand
Is this relevant?
Review
2007
Review
2007
Currently, beta-emitting radionuclides are used almost exclusively in the clinic and in clinical radioimmunotherapy studies. The… Expand
  • table 1
  • figure 1
Is this relevant?
2004
2004
6520 Background: A phase II, open-label, multicenter study was conducted to determine the efficacy of Bexxar therapy following… Expand
Is this relevant?
2004
2004
6518 Background: The sequential combination of chemotherapy and radioimmunotherapy offers a novel strategy for the initial… Expand
Is this relevant?
Review
2004
Review
2004
Patients with low grade (LG) non-Hodgkin's lymphomas (NHLs) typically have a median survival of 8-10 years during which they… Expand
Is this relevant?
2004
2004
6575 Introduction: The Bexxar therapeutic regimen can produce durable and complete responses in patients with relapsed/refractory… Expand
Is this relevant?
Review
2002
Review
2002
  • Bruce D Cheson
  • Current opinion in investigational drugs
  • 2002
  • Corpus ID: 7664533
Bexxar (131I tositumomab) is a radiolabeled anti-CD20 monoclonal antibody for the treatment of relapsed and refractory follicular… Expand
Is this relevant?
2002
2002
BACKGROUND Radioimmunotherapy (RIT) with Bexxar (tositumomab and iodine-131 tositumomab; Coulter Pharmaceutical, South San… Expand
Is this relevant?